((自动化翻译由路透提供，请见免责声明 ))
路透11月23日 - 美国食品和药物管理局已批准了BridgeBio公司 治疗一种罕见致命心脏病的药物，该公司周五表示，这使它成为辉瑞 大片Vyndaqel主导的市场上的第一种新疗法。
这种口服药物的品牌为Attruby，被批准用于治疗患有转甲状腺素淀粉样心肌病的成年患者(ATTR-CM)，这种病的转甲状腺素蛋白在心脏中积聚，可导致器官衰竭。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.